Bradley Foster & Sargent’s Teva Pharmaceuticals TEVA Stock Holding History

Bradley Foster & Sargent’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-6,151	Closed	-$223K	–	355
2016 Q4	$223K	Buy	6,151 +1,401	+29%	+$55.9K	0.01%	327
2016 Q3	$219K	Hold	4,750	–	–	0.01%	321
2016 Q2	$239K	Buy	4,750 +100	+2%	+$5.32K	0.01%	304
2016 Q1	$249K	Hold	4,650	–	–	0.01%	296
2015 Q4	$305K	Sell	4,650 -753	-14%	-$46.5K	0.01%	276
2015 Q3	$305K	Hold	5,403	–	–	0.02%	285
2015 Q2	$319K	Hold	5,403	–	–	0.01%	297
2015 Q1	$337K	Buy	5,403 +195	+4%	+$11.3K	0.02%	294
2014 Q4	$300K	Sell	5,208 -500	-9%	-$27.9K	0.01%	290
2014 Q3	$307K	Buy	5,708 +563	+11%	+$29.8K	0.01%	298
2014 Q2	$270K	Buy	+5,145	New	+$263K	0.01%	304
2014 Q1	–	Sell	-37,580	Closed	-$1.51M	–	350
2013 Q4	$1.51M	Sell	37,580 -1,754	-4%	-$69.1K	0.08%	162
2013 Q3	$1.49M	Buy	39,334 +338	+0.9%	+$13.2K	0.09%	150
2013 Q2	$1.53M	Buy	+38,996	New	+$1.52M	0.09%	141

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bradley Foster & Sargent's TEVA Position: Q1 2017 in Review

Bradley Foster & Sargent sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 6,151 shares — an estimated $223K sold.

Bradley Foster & Sargent first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $1.53M in Q2 2013. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Bradley Foster & Sargent reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Bradley Foster & Sargent sold 6,151 Teva Pharmaceuticals shares in Q1 2017, an estimated $223K.
Bradley Foster & Sargent first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Bradley Foster & Sargent's Teva Pharmaceuticals position peaked at $1.53M in Q2 2013.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Bradley Foster & Sargent's 13F filing for Q1 2017, filed 12 May 2017.